hotspot -WSS

hotspot

author：focus 2025-10-01 18:23:16 - browse：35873

An effective treatment for Alzheimer’s disease has long been a holy grail in the pharmaceutical industry. In early June, some hope appeared when the FDA agreed that the anti-amyloid antibody lecanemab (to be sold by Eisai as Leqembi) outperformed placebo in trials. It is expected to receive full approval by July 6.

But this may not necessarily be purely good news.

On the latest episode of the “First Opinion Podcast,” physician and professor Jason Karlawish argues that lecanemab and other promising new drugs, such as donanemab, will introduce complicated issues into the field of Alzheimer’s care. These medications require a great deal of testing and patient monitoring, trained physicians, and other resources in a system that is already stretched thin.

“Dr. Karlawish’s dream of reason would be … a training module for physicians to learn the key things they need to learn and then self-assess their comfort with the drug,” Karlawish said. “But that’s Karlawish’s dream of reason in a world that seems increasingly less reasonable sometimes.”

Karlawish is a professor of medicine, medical ethics and health policy, and neurology at the University of Pennsylvania’s Perelman School of Medicine. The conversation is based off his recent First Opinion, “The FDA needs a risk evaluation and mitigation strategy for Alzheimer’s drug lecanemab.“

Be sure to sign up for the weekly “First Opinion Podcast” on Apple Podcasts, Stitcher, Google Play, or wherever you get your podcasts.

Previous article： Duchenne breakthrough therapy leaves behind pioneering families
Next article： More hospitals are billing patients as online messages surge

leisure time

WSS

Britain’s MI6 chief says his spies are using AI to disrupt flow of weapons to Russia

Why you get paid to donate plasma but not blood

At flashy new research hub, AstraZeneca lays out ambitious growth goals

Liver decline slowed by off

H5N1 virus can be tracked in retail milk, scientists say

Making the case for fair compensation in clinical trials

focus

hotspot

entertainment

Supreme Court strikes down use of affirmative action

BridgeBio heart drug succeeds in pivotal study

Tori Bowie and the unacceptable rates of Black maternal death

Digital health: a case of mistaken identity

Activists slam private health insurers over coverage restrictions

As a primary care physician, here's how I hope to partner with AI

The cancer drug shortage isn’t new — and neither are the solutions

Israeli protesters block highways, train stations as Netanyahu moves ahead with judicial overhaul

Jerome Adams on the need for new antivirals for Covid

A strong 6.5

entertainment

H5N1 virus can be tracked in retail milk, scientists say

A strong 6.5

A look at other Americans who have crossed into North Korea over the years

Search resumes for 2 missing children washed away with mom in deadly Pennsylvania flash flood

H5N1 bird flu outbreak: Second human case reported, in Michigan

Asa Hutchinson previews new plan to reform federal law enforcement if elected in 2024

focus

leisure time

hotspot

focus